A recent clinical trial showed that a significant progression-free and overall survival benefit was associated with maintenance chemotherapy in patients with HER2-negative metastatic breast cancer who have disease control after six cycles of conventional chemotherapy. However, the choice of observation alone as the control arm limits the clinical application of these data.
- Miguel Martín
- Sara López-Tarruella
